Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The obsessive–compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive–compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety. Disorders that include these features can be grouped according to the focus of the symptoms, e.g., bodily preoccupation (i.e., eating disorders, ED) or impulse control (i.e., substance use disorders, SUD), and they exhibit intriguing similarities in phenomenology, etiology, pathophysiology, patient characteristics and clinical outcomes. The non-competitive N-methyl-D-aspartate receptor (NMDAr) antagonist ketamine has been indicated to produce remarkable results in patients with treatment-resistant depression, post-traumatic stress disorder and OCD in dozens of small studies accrued over the past decade, and it appears to be promising in the treatment of SUD and ED. However, despite many small studies, solid evidence for the benefits of its use in the treatment of OCD spectrum and addiction is still lacking. Thus, the aim of this perspective article is to examine the potential for ketamine and esketamine in treating OCD, ED and SUD, which all involve recurring and intrusive thoughts and generate associated compulsive behavior. A comprehensive and updated overview of the literature regarding the pharmacological mechanisms of action of both ketamine and esketamine, as well as their therapeutic advantages over current treatments, are provided in this paper. An electronic search was performed, including all papers published up to April 2021, using the following keywords (“ketamine” or “esketamine”) AND (“obsessive” OR “compulsive” OR “OCD” OR “SUD” OR “substance use disorder” OR “addiction” OR “craving” OR “eating” OR “anorexia”) NOT review NOT animal NOT “in vitro”, on the PubMed, Cochrane Library and Web of Science online databases. The review was conducted in accordance with preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The use and efficacy of ketamine in SUD, ED and OCD is supported by glutamatergic neurotransmission dysregulation, which plays an important role in these conditions. Ketamine’s use is increasing, and preliminary data are optimistic. Further studies are needed in order to better clarify the many unknowns related to the use of both ketamine and esketamine in SUD, ED and OCD, and to understand their long-term effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 2×
“and synaptogenesis, and eventually favor the restoration of synaptic function [9,12,23,25]; additional effects mediated by the modulation of monoaminergic neurotransmission can-”
BackgroundWilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Ketamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418 · cited 2×
“activating the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAr), which are both suggested to play a role in the antidepressant effects of ketamine [20,21].”
BackgroundRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 9×
“Inclusion criteria were: scoring > 8 on the AUDIT; not meeting SCID criteria for AUD at screening; consuming > 40 (M) or > 30 (F) units/week (1 unit = 8 g ethanol), primarily drinking beer; non-treatment seeking NA Ketamine infusion produced a reduction in the reinforcing effects of alcohol among harmful drinkers.”
BackgroundMethodInfluentialKetamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209 · cited 8×
“Not recorded Veraart et al., 2020 [13] 1 F (55 years old) Oral esketaminetreatment NA Oral esketamine treatment started at 0.5 mg/kg twice weekly and was titrated to 2.0 mg/kg 6 weeks MDD who previously was resistant to ECT and DBS comorbid with psychotic and obsessive symptoms Venlafaxine 300 mg; Clozapine 450 mg; Gl…”
BackgroundInfluentialWitt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202
Research works printed but not linked: 63
- Nasir, 2020, Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology, Front. Psychiatry, 11, 548505, 10.3389/fpsyt.2020.548505 · DOI
- Hollander, 1995, Obsessive-compulsive spectrum disorders, J. Clin. Psychiatry, 56, 7
- Pittenger, 2015, Glutamatergic agents for OCD and related disorders, Curr. Treat. Options Psychiatry, 2, 271, 10.1007/s40501-015-0051-8 · DOI · Paper page
- Karthik, 2020, Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives, Neuropsychiatr. Dis. Treat., 16, 1003, 10.2147/NDT.S211703 · DOI
- Bartoli, 2017, Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis, Neurosci. Biobehav. Rev., 77, 232, 10.1016/j.neubiorev.2017.03.010 · DOI
- Strasburger, 2017, What is the mechanism of Ketamine’s rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities, J. Clin. Pharm. Ther., 42, 147, 10.1111/jcpt.12497 · DOI · Paper page
- Veraart, 2021, Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities, BMJ Case Rep., 14, e238135, 10.1136/bcr-2020-238135 · DOI
- Kohtala, S. (2021). Ketamine-50 years in use: From anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol. Rep. · DOI · Paper page
- Peyrovian, 2020, Registered clinical trials investigating ketamine for psychiatric disorders, J. Psychiatr. Res., 127, 1, 10.1016/j.jpsychires.2020.03.020 · DOI · Paper page
- Cui, 2019, Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine’s Antidepressant Effect, Mol. Neurobiol., 56, 3484, 10.1007/s12035-018-1306-3 · DOI
- Sleigh, 2014, Ketamine—More mechanisms of action than just NMDA blockade, Trends Anaesth. Crit. Care, 4, 76, 10.1016/j.tacc.2014.03.002 · DOI · Paper page
- Ricci, 2011, Chronic ketamine use increases serum levels of brain-derived neurotrophic factor, Psychopharmacology, 215, 143, 10.1007/s00213-010-2121-3 · DOI
- Gautam, 2020, Repurposing Potential of Ketamine: Opportunities and Challenges, Indian J. Psychol. Med., 42, 22, 10.4103/IJPSYM.IJPSYM_228_19 · DOI
- Musazzi, 2013, The action of antidepressants on the glutamate system: Regulation of glutamate release and glutamate receptors, Biol. Psychiatry, 73, 1180, 10.1016/j.biopsych.2012.11.009 · DOI · Paper page
- Douglas, 2007, Mapping the matrix: The ways of neocortex, Neuron, 56, 226, 10.1016/j.neuron.2007.10.017 · DOI · Paper page
- Sorice, 2019, Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD), Curr. Neuropharmacol., 17, 710, 10.2174/1570159X16666180813155017 · DOI · Paper page
- Stahl, S.M. (2017). Prescriber’s Guide: Stahl’s Essential Psychopharmacology, Cambridge University Press. [6th ed.].
- Kleber, H.D., Weiss, R.D., George, T.P., Anton, R., Greenfield, S.F., Kosten, T.R., O’Brien, C.P., Rounsaville, B.J., Strain, E.C., and Ziedonis, D.M. (2021, March 14). Treatment of Patients with Substance Use Disorders Second Edition-Work Group on Substance Use Disorders. Available online: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf.
- Allen, 2003, Obsessive-Compulsive spectrum disorders, Dialogues Clin. Neurosci., 5, 259, 10.31887/dcns.2003.5.3/aallen · DOI · Paper page
- Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, PLoS Med., 6, e1000097, 10.1371/journal.pmed.1000097 · DOI · Paper page
- Adams, 2017, Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder, J. Clin. Psychopharmacol., 37, 269, 10.1097/JCP.0000000000000659 · DOI
- Lalanne, L., Nicot, C., Lang, J., Bertschy, G., and Salvat, E. (2016). Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: A case report. BMC Psychiatry, 16. · DOI
- Mills, 1998, Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions, QJM, 91, 493, 10.1093/qjmed/91.7.493 · DOI · Paper page
- Ocker, 2020, Ketamine and Cognitive Behavioral Therapy for Rapid Opioid Tapering With Sustained Opioid Abstinence: A Case Report and 1-Year Follow-up, Pain Pract., 20, 95, 10.1111/papr.12829 · DOI
- Omoigui, 2011, Use of Ketamine in Ameliorating Opioid Withdrawal Symptoms During an Induction Phase of Buprenorphine, Open Pain J., 4, 1, 10.2174/1876386301104010001 · DOI
- Schwartz, T., Trunko, M.L., Feifel, D., Lopez, E., Peterson, D., Frank, G.K.W., and Kaye, W. (2021). A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression. Clin. Case Rep., 1–7. · DOI · Paper page
- Scolnick, 2020, Remission from Chronic Anorexia Nervosa with Ketogenic Diet and Ketamine: Case Report, Front. Psychiatry, 11, 763, 10.3389/fpsyt.2020.00763 · DOI · Paper page
- Dakwar, 2017, Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: A randomized, crossover trial, Mol. Psychiatry, 22, 76, 10.1038/mp.2016.39 · DOI · Paper page
- Bloch, 2012, Effects of ketamine in treatment-refractory obsessive-compulsive disorder, Biol. Psychiatry, 72, 964, 10.1016/j.biopsych.2012.05.028 · DOI · Paper page
- Niciu, 2013, Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder, J. Psychopharmacol., 27, 651, 10.1177/0269881113486718 · DOI · Paper page
- Jovaisa, 2006, Effects of ketamine on precipitated opiate withdrawal, Medicina, 42, 625
- Krupitsky, 2007, Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence, J. Psychoact. Drugs, 39, 13, 10.1080/02791072.2007.10399860 · DOI · Paper page
- Pradhan, 2020, Combining Ketamine, Brain Stimulation (rTMS) and Mindfulness Therapy (TIMBER) for Opioid Addiction, Cureus, 12, e11798
- Rodriguez, 2016, Can Exposure-Based CBT Extend IV Ketamine’s Effects in Obsessive-Compulsive Disorder? An Open-Label Trial, J. Clin. Psychiatry, 77, 408, 10.4088/JCP.15l10138 · DOI · Paper page
- Rodriguez, 2017, Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder, J. Clin. Psychiatry, 78, 466, 10.4088/JCP.16cr11234 · DOI
- Rodriguez, 2015, In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept, Psychiatry Res., 233, 141, 10.1016/j.pscychresns.2015.06.001 · DOI · Paper page
- Rodriguez, 2016, Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion, J. Clin. Psychiatry, 77, 688, 10.4088/JCP.15l10318 · DOI · Paper page
- Wong, 2015, Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome, Ann. Pharmacother., 49, 14, 10.1177/1060028014555859 · DOI · Paper page
- McAndrew, 2017, A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: Study protocol for a randomised controlled trial, Trials, 18, 159, 10.1186/s13063-017-1895-6 · DOI · Paper page
- Rotge, 2010, The glutamate-based genetic immune hypothesis in obsessive-compulsive disorder. An integrative approach from genes to symptoms, Neuroscience, 165, 408, 10.1016/j.neuroscience.2009.10.043 · DOI
- Gipson, 2014, Rapid, transient synaptic plasticity in addiction, Neuropharmacology, 76, 276, 10.1016/j.neuropharm.2013.04.032 · DOI · Paper page
- Meye, 2015, Cocaine-Evoked negative symptoms require AMPA receptor trafficking in the lateral habenula, Nat. Neurosci., 18, 376, 10.1038/nn.3923 · DOI · Paper page
- Krystal, 2003, Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients, Neuropsychopharmacology, 28, 2020, 10.1038/sj.npp.1300252 · DOI
- Jones, J.L., Mateus, C.F., Malcolm, R.J., Brady, K.T., and Back, S.E. (2018). Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Front. Psychiatry, 9. · DOI · Paper page
- Li, 2019, Generality and opponency of rostromedial tegmental (RMTg) roles in valence processing, eLife, 8, e41542, 10.7554/eLife.41542 · DOI
- Li, 2019, Three Rostromedial Tegmental Afferents Drive Triply Dissociable Aspects of Punishment Learning and Aversive Valence Encoding, Neuron, 104, 987, 10.1016/j.neuron.2019.08.040 · DOI · Paper page
- Williams, 2019, Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism, Mol. Psychiatry, 24, 1779, 10.1038/s41380-019-0503-4 · DOI · Paper page
- Nakazato, 2010, Serum glutamine, set-shifting ability and anorexia nervosa, Ann. Gen. Psychiatry, 9, 29, 10.1186/1744-859X-9-29 · DOI · Paper page
- Levinson, 2016, Clarifying the prospective relationships between social anxiety and eating disorder symptoms and underlying vulnerabilities, Appetite, 107, 38, 10.1016/j.appet.2016.07.024 · DOI · Paper page
- Lechin, 2011, Anorexia nervosa versus hyperinsulinism: Therapeutic effects of neuropharmacological manipulation, Clin. Risk Manag., 7, 53
- Aoki, 2017, Synaptic changes in the hippocampus of adolescent female rodents associated with resilience to anxiety and suppression of food restriction-evoked hyperactivity in an animal model for anorexia nervosa, Brain Res., 1654, 102, 10.1016/j.brainres.2016.01.019 · DOI
- Chen, 2018, Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior, Int. J. Eat. Disord., 51, 1020, 10.1002/eat.22937 · DOI
- Hermens, 2020, Anorexia nervosa, zinc deficiency and the glutamate system: The ketamine option, Prog. Neuro Psychopharmacol. Biol. Psychiatry, 101, 109921, 10.1016/j.pnpbp.2020.109921 · DOI
- Campbell, 2018, New steps for treating alcohol use disorder, Psychopharmacology, 235, 1759, 10.1007/s00213-018-4887-7 · DOI
- Davis, 2017, Pharmacotherapy of eating disorders, Curr. Opin. Psychiatry, 30, 452, 10.1097/YCO.0000000000000358 · DOI · Paper page
- Martinotti, 2010, Pregabalin versus naltrexone in alcohol dependence: A randomised, double-blind, comparison trial, J. Psychopharmacol., 24, 1367, 10.1177/0269881109102623 · DOI · Paper page
- Martinotti, 2007, Efficacy and safety of aripiprazole in alcohol dependence, Am. J. Drug Alcohol Abus., 33, 393, 10.1080/00952990701313660 · DOI
- Breeksema, 2020, Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies, CNS Drugs, 34, 925, 10.1007/s40263-020-00748-y · DOI · Paper page
- Shulgin, 1979, Profiles of psychedelic drugs, J. Psychedelic Drugs, 11, 355, 10.1080/02791072.1979.10471421 · doi:10.1080/02791072.1979.10471421
- Thompson, 2020, Ketamine induces immediate and delayed alterations of OCD-like behavior, Psychopharmacology, 237, 627, 10.1007/s00213-019-05397-8 · DOI
- American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM–5), American Psychiatric Association. [5th ed.]. · DOI · Paper page
- McNaughton, 2020, Ketamine and neuroticism: A double-hit hypothesis of internalizing disorders, Personal. Neurosci., 3, e2, 10.1017/pen.2020.2 · DOI
- Kokane, 2020, Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant, Behav. Brain Res., 384, 112548, 10.1016/j.bbr.2020.112548 · DOI · Paper page
Cited by
Martinotti, G., Vita, A., Fagiolini, A., Maina, G., Bertolino, A., Dell'Osso, B., Siracusano, A., Clerici, M., Bellomo, A., Sani, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.043 · Cited by 146
Self-citationMollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J., Ketzitzidou-Argyri, E., Grabski, M., & Morgan, C. J. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695335 · Cited by 65
“Finally, the final theme (6) relates to the transformational effects of the”
BackgroundRobison, R., Lafrance, A., Brendle, M., Smith, M., Moore, C., Ahuja, S., Richards, S., Hawkins, N., & Strahan, E. (2022) · Journal of Eating Disorders · doi:10.1186/s40337-022-00588-9 · Cited by 36
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Ragnhildstveit, A., Slayton, M., Jackson, L. K., Brendle, M., Ahuja, S., Holle, W., Moore, C., Sollars, K., Seli, P., & Robison, R. (2022) · Brain Sciences · doi:10.3390/brainsci12030382 · Cited by 35
Zheng, W., Gu, L.-M., Zhou, Y.-L., Wang, C.-Y., Lan, X.-F., Zhang, B., Shi, H.-S., Wang, D.-F., & Ning, Y.-P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780975 · Cited by 12
Metadata
- Authors
- Martinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Di Carlo, F., D’Andrea, G., Collevecchio, R., Di Muzio, I., Sensi, S. L., & Di Giannantonio, M.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-27
- Volume
- 11
- Issue
- 7
- Pages
- 856
- ISSN
- 2076-3425 (ISSN-L)
- OpenAlex
- W3175732576
- Cited by
- 111
- References
- 33
- FWCI
- 9.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. https://app.cochat.ai/papers/10.3390/brainsci11070856
- The paper
- Martinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Di Carlo, F., D’Andrea, G., Collevecchio, R., Di Muzio, I., Sensi, S. L., & Di Giannantonio, M. (2021). Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sciences. https://doi.org/10.3390/brainsci11070856
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.